RxDoctor Payments Data

Leelamma George, MD

Internal Medicine · Colonial Heights, VANPI 1306886007

Payments from drug & device makers

$2,062in general payments, 2019–2025

Across 109 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$373
  • AstraZeneca$239
  • Astellas Pharma US Inc$222
  • Novo Nordisk$147
  • Johnson & Johnson$105
  • AbbVie$104
  • plus $873 from 20 others

What the payments were for

  • Food & beverage$1,98796%
  • Education$754%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,062 in reported general payments places this provider in the 80th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$129,095
Medicare patients
311
Services billed
1,066

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin131$147,950
TrulicityDulaglutide64$71,162
OzempicSemaglutide52$61,386
JanuviaSitagliptin Phosphate42$36,677
JanumetSitagliptin Phos/Metformin Hcl39$34,927
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$33,473
MounjaroTirzepatide30$31,727
LinzessLinaclotide47$31,468
FarxigaDapagliflozin Propanediol34$31,261
EliquisApixaban25$24,453
CreonLipase/Protease/Amylase28$23,676
XareltoRivaroxaban22$14,228
SymbicortBudesonide/Formoterol Fumarate23$7,033
BelsomraSuvorexant11$6,545
Lantus SolostarInsulin Glargine,hum.Rec.Anlog51$5,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$86$147,950131 claims
Lilly USA, LLCTrulicity, Mounjaro$33$102,89094 claims
MerckJanuvia, Janumet, Belsomra$83$78,14992 claims
Novo NordiskOzempic$147$61,38652 claims
AbbVieLinzess, Creon$104$55,14575 claims
AstraZenecaFarxiga, Symbicort$239$38,29457 claims
GSKTrelegy Ellipta, Breo Ellipta$373$38,12153 claims
PfizerEliquis$92$24,45325 claims
Johnson & JohnsonXarelto$105$14,22822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Colonial Heights

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →